Jak2 inhibitors (AstraZeneca)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameJak2 inhibitors (AstraZeneca)
Drug Alias NameAZ-01 (AstraZeneca)AZ-60
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitors
TargetsTyrosine-protein kinase JAK2
Therapy Area/IndicationsMyeloproliferative Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsMyeloproliferative Disorders

Other Information

ATC CodeN/A
Related LinksN/A